Galvani Bioelectronics
Galvani Bioelectronics is a Spinal & Peripheral Interfaces company founded in 2016 and based in Stevenage, United Kingdom.
Joint venture between GSK and Verily developing bioelectronic medicines that modulate peripheral nerves for chronic disease treatment. GSK owns majority stake; Verily (Alphabet) holds minority. Programs target inflammatory bowel disease, rheumatoid arthritis, and diabetes via vagus nerve modulation.
Backed by pharma and tech giants, Galvani is pursuing large-scale clinical validation of peripheral nerve interfaces as a drug alternative, bridging BCI and bioelectronic medicine.
galvani.bio ↗·Spinal & Peripheral Interfaces·
United Kingdom·private 
